Newsroom | 26744 results

BORDEAUX, France--(BUSINESS WIRE)--HeartFocus, AI-enabled cardiac imaging software developed by data-driven medtech company DESKi, has announced its expansion to any cart-based system with the launch of HeartFocus Link. Available now for medical schools, residency, and ultrasound training programs, HeartFocus Link addresses one of the most persistent barriers in cardiac ultrasound education and adoption: the challenge of helping healthcare professionals build confidence and competency using the...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the latest results from its mission to build Multimodal Foundation Models at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Tempus has been building novel biological foundation models and agentic workflows by leveraging its more than 500 petabytes of rich, molecularly grounded data—more than 45 million total de-identified...

SAN FRANCISCO--(BUSINESS WIRE)--Ambience Healthcare, the leading intelligence platform for clinical documentation and revenue integrity, today announced a significant expansion of chart-aware intelligence across its inpatient platform. Ambience previously introduced chart awareness, enabling AI to read and reason over a patient's full record rather than the conversation from a single encounter. With this expansion, chart-aware intelligence now covers every step of the hospital stay, from admiss...

NEW YORK--(BUSINESS WIRE)--The Pershing Square Foundation (the “Foundation”) today announced $6 million in funding to support eight pioneering scientists advancing innovative ovarian cancer research across the United States. For more than a decade, the Foundation has advanced transformative cancer research through the Pershing Square Sohn Cancer Research Alliance (“PSSCRA”). Building on its longstanding commitment to cancer research and women’s health, the Foundation is now in the second year o...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a tumor-only indication for its xT CDx next-generation sequencing platform. With this expanded label, Tempus is the first laboratory to hold FDA companion diagnostic (CDx) approval for both tumor-only and tumor-normal comprehensive genomic profiling. Tempus xT CDx is a 648...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will participate in the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting, taking place May 29 – June 2, 2026 in Cleveland, Ohio. At the meeting, NeuroPace will highlight the expanding role of responsive neuromodulation in epilepsy care, including long-term clinical out...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced FDA approval of ECoG Assistant, its first AI-driven clinician-enabled feature. This milestone represents an important step in NeuroPace’s broader AI platform strategy, leveraging the world’s only long-term intracranial EEG dataset to transform how epilepsy is monitored and managed. ECoG Assistant: Treatment Insights Si...

EDMONTON, Alberta--(BUSINESS WIRE)--Youth Science Canada presented the top awards at the 2026 Canada-Wide Science Fair (CWSF) on Thursday evening in Edmonton, Alta....

EDMONTON, Alberta--(BUSINESS WIRE)--Sciences jeunesse Canada a présenté les grands prix de l'Expo-sciences pancanadienne (ESPC) 2026 jeudi soir à Edmonton (Alb.), où 390 finalistes de partout au Canada ont présenté 344 projets et se sont disputé près de 2 millions de dollars en prix, dans le cadre du plus grand événement en STIM pour les jeunes au Canada. Faits saillants : Liam Desre, de Kingston (Ont.), a remporté le Prix du meilleur projet — Découverte pour avoir proposé un nouveau modèle de...

SAN FRANCISCO--(BUSINESS WIRE)--Rubedo Life Sciences, Inc. (Rubedo), une société de biotechnologie de phase clinique axée sur l’intelligence artificielle et spécialisée dans les médicaments de rajeunissement cellulaire sélectif ciblant les cellules vieillissantes, a annoncé aujourd’hui les résultats préliminaires d’une étude de phase 1b/2a sur RLS-1496 chez des patients atteints de kératose actinique (AK), une affection courante liée à l’âge entraînant des lésions cutanées précancéreuses, qui s...